AMENDMENT

A. Claims

The listing of claims below will replace all prior versions, and listings, of claims in the application. Please amend claims 1 and 21 as follows:

- Claim 1 (currently amended) A radiopharmaceutical macroaggregate composition for the treatment of abnormal tissue comprising particles having a minimum size of one micron, wherein the particles comprise a <u>coprecipitate of a</u> metal and one or more radioactive isotopes, and have sufficient radioactivity for locoregional ablation of cells in the abnormal tissue.
- Claim 2 (original) The composition of claim 1, wherein the radiopharmaceutical macroaggregate composition is paramagnetic.
- Claim 3 (withdrawn) The composition of claim 1, wherein the radiopharmaceutical macroaggregate composition is nonparamagnetic.
- Claim 4 (original) The composition of claim 1, wherein the metal is iron or gadolinium.
- Claim 5 (withdrawn) The composition of claim 1, wherein the metal is calcium.
- Claim 6 (original) The composition of claim 1, wherein the one or more radioactive isotopes are selected from the group consisting of Gallium-67 (⁶⁷Ga), Yttrium-90 (⁹⁰Y), Yttrium-86 (⁸⁶Y), Gallium-68 (⁶⁸Ga), Thallium-201 (²⁰¹Tl), Strontium-89 (⁸⁹Sr), Indium-111 (¹¹¹In), Iodine-131 (¹³¹I), Samarium-153 (¹⁵³Sm), Technetium-99m (^{99m}Tc), Rhenium-186 (¹⁸⁶Re), Rhenium-188 (¹⁸⁸Re), Copper-62 (⁶²Cu), and Copper-64 (⁶⁴Cu).
- Claim 7 (original) The composition of claim 1, wherein the radiopharmaceutical macroaggregate composition comprises particulates or microspheres.
- Claim 8 (original) The composition of claim 7, wherein the particulates or microspheres comprise glass.
- Claim 9 (withdrawn) The composition of claim 7, wherein the particulates or microspheres comprise ceramic.
- Claim 10 (original) The composition of claim 1, wherein the one or more radioactive isotopes emit beta radiations or positrons.

- Claim 11 (original) The composition of claim 1, wherein the particles comprise a metal and one radioactive isotope.
- Claim 12 (original) The composition of claim 11, wherein the radioactive isotope is a cation.
- Claim 13 (withdrawn) The composition of claim 11, wherein the radioactive isotope is an anion.
- Claim 14 (original) The composition of claim 1, wherein the particles comprise a metal and two radioactive isotopes.
- Claim 15 (original) The composition of claim 14, wherein one or both of the radioactive isotope are cations.
- Claim 16 (withdrawn) The composition of claim 14, wherein one or both of the radioactive isotope are anions.
- Claim 17 (withdrawn) The composition of claim 14, wherein one of the radioactive isotopes is Holmium-166 (¹⁶⁶Ho).
- Claim 18 (original) The composition of claim 1, wherein the particles further comprise Phytate.
- Claim 19 (original) The composition of claim 10, wherein the particles further comprise Phytate.
- Claim 20 (original) The composition of claim 14, wherein the particles further comprise Phytate.
- Claim 21 (currently amended) The composition of claim 1, wherein the ratio of radioactive isotopes to metal is about $\frac{10^6}{110^6}$.
- Claim 22 (original) The composition of claim 1, wherein the particles are biodegradable.
- Claim 23 (original) The composition of claim 1, wherein the size of the particles is from about 5 to about 50 microns.
- Claims 24-44 (canceled).
- Claim 45 (withdrawn) A radiopharmaceutical macroaggregate composition for the treatment of abnormal tissue comprising particles having a minimum size of one micron, wherein the particles comprise a metal and one or more radioactive isotopes, and have sufficient radioactivity for locoregional ablation of cells in the abnormal, produced by a process comprising the steps of:

- (a) mixing one or more radioactive isotopes with a metal chloride;
- (b) adding an alkaline to the mixture of part a to precipitate the radioactive isotopes with the metal to form the particles;
- (c) separating the precipitated particles from any remaining soluble radioactive isotopes from the particles; and
- (d) isolating the radioactive particles.
- Claim 46 (withdrawn) The process of claim 45, wherein the metal chloride is selected from the group consisting of ferric chloride (FeCl₃), calcium chloride (CaCl₂), and gandolinium chloride (GdCl₃).
- Claim 47 (withdrawn) The process of claim 45, wherein the alkaline is sodium hydroxide or ammonium hydroxide.
- Claim 48 (withdrawn) A radiopharmaceutical macroaggregate composition for the treatment of abnormal tissue comprising particles having a minimum size of one micron, wherein the particles comprise a metal and one or more radioactive isotopes, and have sufficient radioactivity for locoregional ablation of cells in the abnormal, produced by a process comprising the steps of:
 - (a) adding an alkaline to a metal chloride to form a precipitate;
 - (b) mixing one or more radioactive isotopes with the precipitate of part (a) to allow the radioactive isotopes to adsorb to the precipitate and generate a radioactive precipitate;
 - (c) separating the radioactive precipitate of part (b) from any remaining soluble radioactive isotopes; and
 - (d) isolating the radioactive precipitate.
- Claim 49 (withdrawn) The process of claim 48, wherein the metal chloride is selected from the group consisting of ferric chloride (FeCl₃), calcium chloride (CaCl₂), and gandolinium chloride (GdCl₃).
- Claim 50 (withdrawn) The process of claim 48, wherein the alkaline is sodium hydroxide or ammonium hydroxide.
- Claim 51 (withdrawn) The process of claim 48, wherein the radioactive precipitate of part (b) is separated from any remaining soluble radioactive isotopes by centrifugation.
- Claim 52 (canceled).